ONCS
OncoSec Medical Incorporated
NasdaqCM
People also watch:INOIMUCRNNMSTXGALE
1.790.07 (4.07%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close1.72
Open1.71
Bid1.32 x 100
Ask3.50 x 200
52wk Range1.36 - 6.94
Day's Range1.71 - 1.80
Volume209,872
Avg Vol (3m)156,179
As of 4:00 PM EDT. Market closed.
  • OncoSec Medical, Inc. :ONCS-US: Earnings Analysis: Q2, 2016 By the Numbers
    Capital Cube4 months ago

    OncoSec Medical, Inc. :ONCS-US: Earnings Analysis: Q2, 2016 By the Numbers

    Click here to see latest analysisOncoSec Medical, Inc. reports financial results for the quarter ended January 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -7.04 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.ONCS-US‘s earnings and EBITDA are […] (Read more...) The post OncoSec Medical, Inc. :ONCS-US: Earnings Analysis: Q2, 2016 By the Numbers appeared first on CapitalCube.

  • Zacks Small Cap Research5 months ago

    ONCS: OncoSec Exited Fiscal Second Quarter with a Strong Balance Sheet

    At January 31, 2016, OncoSec had $28.8 million in cash and cash equivalents. In November, 2015, OncoSec closed a registered direct offering with two healthcare focused funds for the purchase of 2,142,860 shares of its common stock at a price of $3.50 and warrants to purchase up to an aggregate of 1,071,430 shares of common stock at an exercise price of $4.50 per share. On June 8, 2015, OncoSec closed a registered direct offering of 2,469,091 shares of its common stock at a price of $5.50 per share.

  • Zackslast year

    Heat Biologics' Bladder Cancer Drug Gets Fast Track Status - Analyst Blog

    Heat's (HTBX) oncology candidate, HS-410, has received fast track designation in the U.S. for the treatment of non-muscle invasive bladder cancer.